Abediterol

Abediterol
Clinical data
Routes of; administration	Inhalation
ATC code	None;
Legal status
Legal status	Experimental;
Pharmacokinetic data
Elimination half-life	24.3 hours
Identifiers
	IUPAC name 5-[(1R)-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}- 1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
CAS Number	915133-65-2;
PubChem CID	11962616;
ChemSpider	10136846 ;
UNII	QXA167CM6F;
KEGG	D10219 ;
ChEMBL	ChEMBL3039530 ;
CompTox Dashboard (EPA)	DTXSID60238605 ;
Chemical and physical data
Formula	C25H30F2N2O4
Molar mass	403.898 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2;
	InChI InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 ; Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N ;

Abediterol (INN)^[2] (codenamed AZD-0548, LAS 100977) is a novel, once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials.^[3]^[4]

Its coformulation with mometasone furoate is also in Phase II clinical trials.^[8]

References

^ Timmer, Wolfgang; Massana, Eric; Jimenez, Eulalia; Seoane, Beatriz; de Miquel, Gonzalo; Ruiz, Sandrine (December 2014). "First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Abediterol (LAS100977), a Novel Long-Acting β₂-agonist". The Journal of Clinical Pharmacology. 54 (12): 1347–53. doi:10.1002/jcph.355.
^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (1): 352. 2010. Retrieved 25 March 2016.
^ Product development pipeline, Almirall
^ "AdisInsight: Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.
^ WO 2006122788
^ WO 2010094484
^ Beier, J; Fuhr, R; Massana, E; Jiménez, E; Seoane, B; de Miquel, G; Ruiz, S (October 2014). "Abediterol (LAS100977), a novel long-acting β₂-agonist: Efficacy, safety and tolerability in persistent asthma". Respiratory Medicine. 108 (10): 1424–1429. doi:10.1016/j.rmed.2014.08.005. PMID 25256258. Retrieved 25 March 2016.
^ "AdisInsight: Abediterol/mometasone". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.